Amgen v Sanofi/Regeneron : a new dawn for inventive step at the Unified Patent Court? Or business as usual for European patent lawyers?
Journal of Intellectual Property Law & Practice · 13.08.2026 · 21 (8) · 527-532
DOI: 10.1093/jiplp/jpag057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Intellectual Property Law & Practice, online erschienen am 08.06.2026. Verfasst von Adrián Crespo Velasco und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Two years into the operation of the Unified Patent Court, Amgen v Sanofi/Regeneron is, alongside Edwards Lifesciences v Meril, the first decision on the merits from the Court of Appeal that tackles the inventive step and sufficiency requirements. This landmark decision might shape European patent litigation before the Unified Patent Court for years to come, particularly in the field of antibody drugs. We critically assess potential differences between the criteria applied by the European Patent Office, the Unified Patent Court and the Supreme Court of the United States.
Zitieren
APA
Velasco, A. C., & Skiebe, D. (2026). Amgen v Sanofi/Regeneron : a new dawn for inventive step at the Unified Patent Court? Or business as usual for European patent lawyers?. Journal of Intellectual Property Law & Practice, 21(8), 527-532. https://doi.org/10.1093/jiplp/jpag057
Vancouver
Velasco AC, Skiebe D. Amgen v Sanofi/Regeneron : a new dawn for inventive step at the Unified Patent Court? Or business as usual for European patent lawyers?. Journal of Intellectual Property Law & Practice. 2026;21(8):527-532. doi:10.1093/jiplp/jpag057
BibTeX
@article{Velasco2026,
author = {Velasco, Adrián Crespo and Skiebe, Daniel},
title = {Amgen v Sanofi/Regeneron : a new dawn for inventive step at the Unified Patent Court? Or business as usual for European patent lawyers?},
journal = {Journal of Intellectual Property Law & Practice},
year = {2026},
volume = {21},
number = {8},
pages = {527--532},
doi = {10.1093/jiplp/jpag057}
}
EUVIMED